| Prev Close | 82.28 |
| Day Low/High | 81.12 / 85.63 |
| 52 Wk Low/High | 13.64 / 109.94 |
| Avg Volume | 802.50K |
Axsome Therapeutics Inc. (AXSM)
83.91
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 37.08M |
| Market Cap | 3.05B |
| EPS | -2.00 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
3 Busted IPOs That Could Be Good Investments
This unloved part of the market has frequently produced some of the biggest gainers within my personal portfolio over the years.
Looking at Cybersecurity Names If the Iran Situation Worsens
I'm far more excited about the potential buys that I see this action creating than I am about the weakness.
Last Year Was One to Hold Your Nose When It Came to IPOs
Despite the strength in equities in 2019, several high-profile initial public offerings landed with large thuds and have struggled since.
This Contrarian Play Is My Pick of the Year for 2020
The antibiotics maker recently received a significant federal contract that could help give its shares the juice they need to climb next year.
Market Action Is Quite Random
The indices moved into positive territory and now the action has cooled off.
Will Profit Taking Hold Off Until 2020?
Traders may try to jump the gun, but there are several factors that may delay the traditional end-of-year stock selloff.
The Heart of Effective Trading Is Finding a Steady Supply of Fresh Ideas
If you stick with the same old names every day, then you are an investor and not a trader; outsize gains require outsize efforts.
Focus on the Trees, Not the Forest
The current market favors stock pickers.
Riding 2 Big Winners in Small Biotech
Reata Pharmaceuticals and Axsome Therapeutics each have had a terrific 2019, which helps offset the losing bets in this high-beta sector of the market.
In Search of That 'Tenbagger'
Here are 2 stocks worthy of small positions within a well-diversified biotech portfolio for aggressive investors.
Bitcoin: A Trading Opportunity in an Asset With No Intrinsic Value
Its price is determined by emotion more than anything else.
6 Stocks on My Radar as Market Support Holds
We should be trading this kind of action, rather than making big market direction calls.
Trump Tweet Traps Market Pessimists
We are now seeing why it is so important to focus on price action rather than the negative arguments.
Here Are the 2 Tasks I Focus on in This Environment
A trade deal will likely emerge but it's not going to be easy and the market is going to be volatile while it awaits.
The GDP Report Took the Wind Out of the Bears' Sails
It is easy to argue that this market should be rolling over but it is not and that means we stick with what is working which are long plays.
On the Hunt for New Buys but Staying Selective
The FAANG names are mixed but there continues to be strong momentum in some select big caps.
Is This Market Action Foreshadowing Something Worse?
This trading is starting to create some fairly deep pullbacks.
Bears Unable to Build Momentum Off Yield Curve Issue
At this juncture the action is looking like nothing more than a routine pullback of an extended market.
Apple Is Going to Drive Overall Market Direction Today
We have to wait for APPL's 1:00 pm ET event before we have a better feel where things are headed.
Why I Make a Myriad of Small Biotech Bets
The fact is there are few more complex areas of the market than the small-cap biotech sector. Patience is key.
Stock Buyers Don't Want to Leave This Party
If you listen to some pundits, you are foolish to trust the trend and should be rushing to sell in order to prepare for the disaster that awaits naive bulls.
Trading Notes for Select Stocks
Here's my take on a list of stocks I've been watching.
Protect Gains as 'Sell the News' Reaction Hits
I have cut a number of positions into China trade news and my timeframe is short.
Three to Watch in Biotech
Other than the Dow, most of major market indices are showing small gains heading into the last hour of trading. The biotech sector has not participated in today's rally and is down some 0.75% on the day so far. I am watching a few small biotech and ...